John Ruffolo

All filings by John Ruffolo on record concern NervGen Pharma Corp. The record holds 5 filings, for trades running from 16 October 2023 to 4 September 2026.

On the market, this insider has only ever bought: 3 purchases, €12k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 1 option exercise. In 2026 alone, the filings show 3 purchases and no sales.

A typical purchase (the median) is worth €204. None of the 3 purchases we analysed coincided with buying by another insider of the same company within 30 days.

Most recently, on 9 September 2026, the filings show an option exercise worth €79k in NervGen Pharma Corp. The most recent open-market purchase was published on 5 August 2026, 96 days ago. The median gap between a trade and its publication by SEDI is 5 days. The shorter that gap, the sooner other investors can see what insiders have done. This summary is built from SEDI disclosures alone and does not predict where the share price will go.